194 related articles for article (PubMed ID: 29472252)
21. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
23. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
25. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
[TBL] [Abstract][Full Text] [Related]
26. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome.
Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Chung DC
Mod Pathol; 2017 Mar; 30(3):440-447. PubMed ID: 28059100
[TBL] [Abstract][Full Text] [Related]
27. Population-based screening for Lynch syndrome in Western Australia.
Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
[TBL] [Abstract][Full Text] [Related]
28. Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.
Kumamoto K; Ishida H; Suzuki O; Tajima Y; Chika N; Kuwabara K; Ishibashi K; Saito K; Nagata K; Eguchi H; Tamaru J; Iwama T
Surg Today; 2016 Jun; 46(6):713-20. PubMed ID: 26249337
[TBL] [Abstract][Full Text] [Related]
29. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
30. A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors.
Agostini M; Enzo MV; Morandi L; Bedin C; Pizzini S; Mason S; Bertorelle R; Urso E; Mescoli C; Lise M; Pucciarelli S; Nitti D
Cancer Biomark; 2010; 6(1):49-61. PubMed ID: 20164541
[TBL] [Abstract][Full Text] [Related]
31. The role of clinical criteria, genetic and epigenetic alterations in Lynch-syndrome diagnosis.
Alemayehu A; Tomkova K; Zavodna K; Ventusova K; Krivulcik T; Bujalkova M; Bartosova Z; Fridrichova I
Neoplasma; 2007; 54(5):391-401. PubMed ID: 17688369
[TBL] [Abstract][Full Text] [Related]
32. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
33. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer.
McGivern A; Wynter CV; Whitehall VL; Kambara T; Spring KJ; Walsh MD; Barker MA; Arnold S; Simms LA; Leggett BA; Young J; Jass JR
Fam Cancer; 2004; 3(2):101-7. PubMed ID: 15340260
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome.
Sinn DH; Chang DK; Kim YH; Rhee PL; Kim JJ; Kim DS; Park CK; Kim JW; Yun SH; Lee WY; Chun HK; Rhee JC
Hepatogastroenterology; 2009; 56(91-92):672-6. PubMed ID: 19621678
[TBL] [Abstract][Full Text] [Related]
35. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
[TBL] [Abstract][Full Text] [Related]
36. Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
Yamada R; Yamaguchi T; Iijima T; Wakaume R; Takao M; Koizumi K; Hishima T; Horiguchi SI
Int J Clin Oncol; 2018 Jun; 23(3):504-513. PubMed ID: 29327160
[TBL] [Abstract][Full Text] [Related]
37. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
38. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
39. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
